Prevalence and treatment patterns among adults with prostate disorder in a tertiary hospital, Bayelsa state, Nigeria
Article Sidebar
Main Article Content
Abstract
Background: The prevalence of prostate disorder in the elderly is usually high due to its association with age. However, changing lifestyle have made prostate disorder to reported in middle age adults in some health care facilities in some parts of the world.
Objectives: This study evaluated the prevalence of prostate disorder, and medication use patterns among middle age adults in a tertiary healthcare facility in Bayelsa State, Nigeria.
Methods: The study was a cross-sectional retrospective study with modified proforma used to assess patients diagnosed with prostate disorder between July 2020 and July 2022. Data on socio-demographics, prevalence and medication use pattern by the patients were collected. Descriptive analysis was done using SPSS version 25. Pearson Chi-square was done to determine the relationship of demographics with prevalence of prostate disorder, with level of significance set at p < 0.05.
Results: The prevalence rate of prostate disorder was 29.2 %, and about one-third (34.8%) were above 60 years old. Tamsulocin (80.4 %) was the most prescribed anti prostate disorder drug, followed by Finasteride (66.3 %). More than one half (60.7 %) of the medications prescribed were antibiotics, with ciprofloxacin accounting for 14.1%%. Surgical procedures were carried out for 84.8% of the patients.
Conclusion: There was high prevalence of prostate disorder with age especially with 61 years and above. High level of poly-pharmacy and overuse of antibiotics in this study center.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
Phua TJ. The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective. Medicines (Basel). 2021 Jun 11;8(6):30. doi: 10.3390/medicines8060030.
Kim EH, Larson JA, Andriole GL (2016)."Management of Benign Prostatic Hyperplasia". Annual Review of Medicine (Review). 67: 137-51.
Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls
Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558920/
Bosch, R., Abrams, P., Averbeck, MA., Finazzi Agró, E., Gammie, A., Marcelissen, T., & Solomon, E. (2019). Do functional changes occur in the bladder due to bladder outlet obstruction?-ICI-RS 2018.Neurourology and urodynamics, 38, S56-S65.
Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia.Cochrane Database Syst Rev. 2010 Oct
;2010(10):CD006015. doi: 10.1002/14651858.CD006015.
Neil Barber, Keng Lim Ng. Considerations forChoosing Treatment Options for Benign Prostatic Hyperplasia. EMJ Urol. 2021;9[1]:63-70
Silva V, Grande AJ, Peccin MS (2019). "Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction". The Cochrane Database of Systematic Reviews. 2019 (4):CD012044. doi:10.1002/14651858.CD012044
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M. (2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 19902010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163-96. doi:10.1016/S0140-6736(12)61729-2.
Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. (2012). Endocrinology of the Aging Prostate: Current Concepts. Front Endocrinol (Lausanne). 22;12:554078. doi: 10.3389/fendo.2021.554078.
Badshah, M.; Ibrahim, J.; Su, N.; Whiley, P.; Whittaker, M.; Exintaris, B. (2023). The Effects of Age on Prostatic Responses to Oxytocin and the Effects of Antagonists. Biomedicines. 11, 2956. https://doi.org/10.3390/biomedicines11112956
Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W. (2002)."Incidence and prevalence of lower urinary tract
symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project". European Urology. 42 (4): 323-8
NPC, (2006). National Population Commission,National Census Conducted Across the 36 States in Nigeria.
Ozims, S., Agu, G., Amah, H., Eberendu, IF., ObiomaElemba, JE., Ihekaire, DE., & Nwosu, DC. (2018). Prevalence of prostate disorder among males> 50 years of age who were treated at Abia State University Teaching Hospital, Aba from 20102014. International Journal of Research Studies in Medical and Health Sciences, 3(1), 1-7.
Bosland, MC., Nettey, OS., Phillips, AA., Anunobi, CC., Akinloye, O., Ekanem, IOA., & Murphy, AB. (2021). Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report. The Prostate, 81(9), 553-559.
Ojewola, RW., Oridota, ES., Balogun, OS., Alabi, TO., Ajayi, AI., Olajide, TA., & Ogundare, EO. (2017). Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a SouthWestern Nigerian rural setting: A crosssectional study. African Journal of Urology, 23(2), 109-115.
Ukoli, F., Osime, U., Akereyeni, F., Okunzuwa, O., Kittles, R., & Lucile AC. (2003). Prevalence of elevated serum prostate?specific antigen in rural
Nigeria. International Journal of Urology, 10(6), 315322.
Vlotman-Novinuk, D. (2019). Treatment options for benign prostate disorder. Journal of Prescribing Practice, 1(3), 130-138.
Ojewola, RW., Tijani, KH., Fatuga, AL., Onyeze, CI., & Okeke, CJ. (2020). Management of a giant prostatic enlargement: Case report and review of the literature. Nigerian Postgraduate Medical Journal, 27(3), 242-247.
Badmus, TA., Adesunkanmi, ARK., Yusuf, BM., Oseni, GO., Eziyi, AK., Bakare, TI., and Badmus, S. A. (2010). Burden of prostate cancer in southwestern Nigeria. Urology, 76(2), 412-416.